Bridging gap in the treatment of Alzheimer’s disease via postbiotics: Current practices and future prospects

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102689 - 102689

Published: Feb. 1, 2025

Language: Английский

---

Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases

ACS Omega, Journal Year: 2024, Volume and Issue: 9(33), P. 35223 - 35242

Published: Aug. 5, 2024

Neurodegenerative diseases, encompassing conditions such as Alzheimer's disease, Parkinson's multiple sclerosis, amyotrophic lateral prion and Huntington's present a growing health concern human life expectancy increases. Despite this, effective treatments to halt disease progression remain elusive due various factors, including challenges in drug delivery across physiological barriers like the blood-brain barrier patient compliance issues leading treatment discontinuation. In response, innovative approaches leveraging noninvasive techniques with higher are emerging promising alternatives. This Review aims synthesize current options encountered managing neurodegenerative while also exploring modalities. Specifically, strategies intranasal administration nanosized systems gaining prominence for their potential enhance efficacy adherence. Nanosized systems, liposomes, polymeric micelles, nanoparticles, evaluated within context of outstanding studies. The advantages disadvantages these discussed, providing insights into therapeutic limitations. Through this comprehensive examination, contributes ongoing discourse surrounding development diseases.

Language: Английский

---

Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(1), P. 127 - 127

Published: Jan. 18, 2025

Peptide-loaded poly(lactide-co-glycolide) (PLGA) nanocarriers represent a transformative approach to addressing the challenges of peptide-based therapies. These systems offer solutions peptide instability, enzymatic degradation, and limited bioavailability by providing controlled release, targeted delivery, improved stability. The versatility PLGA extends across therapeutic domains, including cancer therapy, neurodegenerative diseases, vaccine development, regenerative medicine. Innovations in polymer chemistry, surface functionalization, advanced manufacturing techniques, such as microfluidics electrospraying, have further enhanced efficacy scalability these systems. This review highlights key physicochemical properties, preparation strategies, proven benefits peptide-loaded systems, emphasizing their role sustained drug immune activation, tissue regeneration. Despite remarkable progress, production scalability, cost, regulatory hurdles remain.

Language: Английский

---

Surface modified proteins and peptides for targeted drug delivery

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Natural bioactive compounds form herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 7, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Glycogen synthase kinase 3β (GSK-3β) plays pivotal role in AD pathogenesis, particularly tau protein hyperphosphorylation. Natural bioactive compounds have wide range of sources, medicinally valuable active compound can be extracted from plants, animals, microorganisms. Currently, studies found that various natural plants the potential to improve symptoms, such as resveratrol berberine. Therefore, this review examines modulate GSK-3β activity inhibit hyperphosphorylation tau, offering promising therapeutic strategy for AD. We summarize current understanding alkaloids, phenols, flavonoids, terpenoids other compounds, highlighting their mechanisms action preclinical efficacy.

Language: Английский

---

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Cell Proliferation, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 11, 2025

ABSTRACT In spite of great advances in modern medicine, there are a few effective strategies for the treatment neurodegenerative diseases characterised by neuron loss or degeneration. This results from complex pathogenesis and limited drug uptake brain due to presence blood‐brain barrier. Nanoparticle‐based delivery systems expected improve utilisation. Polymeric nanoparticles represent promising carriers their unique advantages such as good biodegradability biocompatibility, flexibility surface modification nontoxicity. addition, genetic drugs may stop progression at level even avoid irreversible damage central nervous system. this review, an overview studies on polymer‐based system typical diseases, especially Alzheimer's Parkinson's is described. Meanwhile, applications gene these disorders discussed. And challenges future perspectives development polymeric concluded.

Language: Английский

---

Identification of key genes and signaling pathway in the pathogenesis of Huntington's disease via bioinformatics and next generation sequencing data analysis

Egyptian Journal of Medical Human Genetics, Journal Year: 2025, Volume and Issue: 26(1)

Published: March 4, 2025

Abstract Background Huntington's disease (HD) could cause progressive motor deficits, psychiatric symptoms, and cognitive impairment. With the increasing use of pharmacotherapies theoretically target neurotransmitters, incidence HD is still not decreasing. However, molecular pathogenesis have been illuminate. It momentous to further examine HD. Methods The next generation sequencing dataset GSE105041 was downloaded from Gene Expression Omnibus (GEO) database. Using DESeq2 in R bioconductor package screen differentially expressed genes (DEGs) between samples normal control samples. ontology (GO) term REACTOME pathway enrichment were performed on DEGs. Meanwhile, using Integrated Interactions Database (IID) database Cytoscape software construct protein–protein interaction (PPI) network module analysis, identify hub with highest value node degree, betweenness, stress closeness scores. miRNA-hub gene regulatory TF-hub constructed analyzed. Receiver operating characteristic curves analysis for diagnostic genes. Results We identified 958 DEGs, consisting 479 up regulated DEGs down GO terms analyses by g:Profiler online results revealed that mainly enriched multicellular organismal process, developmental signaling GPCR MHC class II antigen presentation. Network Analyzer plugin PPI network, LRRK2, MTUS2, HOXA1, IL7R, ERBB3, EGFR, TEX101, WDR76, NEDD4L COMT selected as Hsa-mir-1292-5p, hsa-mir-4521, ESRRB SREBF1 are potential biomarkers predicted be associated Conclusion This study investigated key pathways interactions its complications, which might help reveal correlation complications. current investigation captured prediction, follow-up biological experiments enforced validation.

Language: Английский

---

NLRP3 inflammasome in neuroinflammation and central nervous system diseases

Cellular and Molecular Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Abstract Neuroinflammation plays an important role in the pathogenesis of various central nervous system (CNS) diseases. The NLRP3 inflammasome is intracellular multiprotein complex composed innate immune receptor NLRP3, adaptor protein ASC, and protease caspase-1. activation can induce pyroptosis release proinflammatory cytokines IL-1β IL-18, thus playing a inflammatory responses. Recent studies have revealed that activated brain to neuroinflammation, leading further neuronal damage functional impairment, contributes pathological process neurological diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s stroke. In this review, we summarize neuroinflammation course CNS diseases discuss potential approaches target for treatment

Language: Английский

---

Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective

JACS Au, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Alzheimer's disease (AD) is a complex neurodegenerative disorder and the most common cause of dementia. By 2050, number AD cases projected to exceed 131 million, placing significant strain on healthcare systems economies worldwide. The pathogenesis multifactorial, involving hypotheses/mechanisms, such as amyloid-β (Aβ) plaques, tau protein hyperphosphorylation, cholinergic neuron damage, oxidative stress, inflammation. Despite extensive research, complexity these potentially entangled mechanisms has hindered development treatments that can reverse progression. Nanotechnology, leveraging unique physical, electrical, magnetic, optical properties nanomaterials, emerged promising approach for treatment. In this Perspective, we first outlined major current pathogenic hypotheses then reviewed recent advances in nanomaterials addressing hypotheses. We have also discussed challenges translating into clinical applications proposed future directions, particularly multifunctional multitarget enhance their therapeutic efficacy applicability

Language: Английский

---

Neuroprotective potential of tranilast in streptozotocin-induced sporadic Alzheimer's disease model targeting TXNIP-NLRP3 inflammasome pathway

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 156, P. 114691 - 114691

Published: April 23, 2025

Language: Английский

---